Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
sirukumab
Biotech
Johnson & Johnson drops sirukumab, cans phase 3 AML trial
Johnson & Johnson had painted sirukumab and talacotuzumab as future blockbusters that would drive growth for years. Today, J&J abandoned those plans.
Nick Paul Taylor
Oct 17, 2017 10:02am
FDA rejects Johnson & Johnson’s rheumatoid arthritis drug sirukumab
Sep 25, 2017 9:30am
FDA panel snubs J&J’s rheumatoid arthritis drug sirukumab
Aug 3, 2017 5:35am
GSK, Janssen submit sirukumab in Europe, planning for 2016 FDA filing
Sep 13, 2016 8:30am
